Diabetes and cancer relationships.

作者: Tiange Wang , Guang Ning , Zachary Bloomgarden

DOI: 10.1111/1753-0407.12057

关键词:

摘要: Diabetes and cancer are both heterogeneous multifactorial diseases with tremendous impact on health worldwide. Epidemiologic evidence suggests that certain malignancies may be associated diabetes, as well diabetes risk factors and, perhaps, treatments. Numerous biological mechanisms could account for these relationships. Insulin-like growth factor (IGF)-1, IGF-2, IGF-1 receptors, insulin, the insulin receptor play roles in development progression of cancers. Although from randomized controlled trials does not support or refute associations its treatments either increased reduced incidence prognosis, consideration malignancy rates magnitude would required to address issues explains why such studies readily undertaken. 摘要 糖尿病与肿瘤都是异质性的多因素疾病,严重影响全球人类健康。流行病学证据揭示,某些恶性肿瘤与糖尿病、糖尿病危险因素和某些降糖药物密切相关。多种生物学机制可以解释这些关联。胰岛素样生长因子(IGF)-1、IGF-2、IGF-1受体、胰岛素和胰岛素受体均参与了某些肿瘤的发生和发展。尽管众多随机对照试验尚未得出糖尿病及其治疗药物影响肿瘤发生和发展的明确结论,恶性肿瘤的发病率以及解决该问题所需的研究规模决定了该类研究的实施难度。

参考文章(166)
Jan Hammarsten, Benkt Högstedt, Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer European Journal of Cancer. ,vol. 41, pp. 2887- 2895 ,(2005) , 10.1016/J.EJCA.2005.09.003
Philip D Home, Stuart J Pocock, Henning Beck-Nielsen, Paula S Curtis, Ramon Gomis, Markolf Hanefeld, Nigel P Jones, Michel Komajda, John JV McMurray, Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial The Lancet. ,vol. 373, pp. 2125- 2135 ,(2009) , 10.1016/S0140-6736(09)60953-3
M. J. Gunter, D. R. Hoover, H. Yu, S. Wassertheil-Smoller, T. E. Rohan, J. E. Manson, J. Li, G. Y. F. Ho, X. Xue, G. L. Anderson, R. C. Kaplan, T. G. Harris, B. V. Howard, J. Wylie-Rosett, R. D. Burk, H. D. Strickler, Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women Journal of the National Cancer Institute. ,vol. 101, pp. 48- 60 ,(2009) , 10.1093/JNCI/DJN415
G. B. Bolli, A. D. Hahn, R. Schmidt, T. Eisenblaetter, R. Dahmen, T. Heise, R. H. A. Becker, Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes Diabetes Care. ,vol. 35, pp. 2626- 2630 ,(2012) , 10.2337/DC12-0270
J. Rosenstock, V. Fonseca, J. B. McGill, M. Riddle, J. P. Hallé, I. Hramiak, P. Johnston, M. Davis, Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. ,vol. 52, pp. 1971- 1973 ,(2009) , 10.1007/S00125-009-1452-2
Sharon H Saydah, Catherine M Loria, Mark S Eberhardt, Frederick L Brancati, Abnormal Glucose Tolerance and the Risk of Cancer Death in the United States American Journal of Epidemiology. ,vol. 157, pp. 1092- 1100 ,(2003) , 10.1093/AJE/KWG100
D. P. Rose, D. Komninou, G. D. Stephenson, Obesity, adipocytokines, and insulin resistance in breast cancer Obesity Reviews. ,vol. 5, pp. 153- 165 ,(2004) , 10.1111/J.1467-789X.2004.00142.X
Chia-Hsuin Chang, Jou-Wei Lin, Li-Chiu Wu, Mei-Shu Lai, Lee-Ming Chuang, Oral Insulin Secretagogues, Insulin, and Cancer Risk in Type 2 Diabetes Mellitus The Journal of Clinical Endocrinology and Metabolism. ,vol. 97, ,(2012) , 10.1210/JC.2012-1162
Veronica Vella, L Sciacca, G Pandini, R Mineo, S Squatrito, R Vigneri, A Belfiore, The IGF system in thyroid cancer: new concepts. Molecular pathology : MP. ,vol. 54, pp. 121- 124 ,(2001) , 10.1136/MP.54.3.121
Andrew G. Renehan, Jan Frystyk, Allan Flyvbjerg, Obesity and cancer risk: the role of the insulin-IGF axis. Trends in Endocrinology and Metabolism. ,vol. 17, pp. 328- 336 ,(2006) , 10.1016/J.TEM.2006.08.006